Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24106790 | 0.74 | ALDH1A1 (0.36) | TSHRLMNAHTTKMT2ACYP2B6 | |
| SCHEMBL12359948 | 0.74 | SMN1; SMN2 (0.34) | TSHRALDH1A1MAPK1SMN1; SMN2RECQL | |
| SCHEMBL27350385 | 0.72 | CYP2B6 (0.42) | CYP2B6 | |
| SCHEMBL20436456 | 0.72 | CYP2B6 (0.42) | CYP2B6 | |
| SCHEMBL22699698 | 0.71 | ALDH1A1 (0.37) | TSHRLMNAHTTKMT2AALDH1A1 | |
| SCHEMBL946474 | 0.71 | TSHR (0.35) | TSHRLMNAMAPTHTTKMT2A | |
| SCHEMBL679559 | 0.70 | PDK1 (0.34) | TSHRALDH1A1MAPK1SMN1; SMN2RECQL | |
| SCHEMBL24995560 | 0.70 | ALDH1A1 (0.40) | TSHRCYP2B6ALDH1A1 | |
| SCHEMBL4320387 | 0.69 | ALDH1A1 (0.42) | TSHRKMT2AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL22756187 | 0.69 | CYP2B6 (0.39) | CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | TSHR 3383/4885LMNA 2182/4885MAPT 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.